scholarly journals Cognitive Screening Tool in Parkinson’s Disease: Mini Mental State Examination (MMSE) Versus Montreal Cognitive Assessment (Moca)

2012 ◽  
Vol 01 (S1) ◽  
Author(s):  
Arun Aggarwal
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mental State ◽  
Cognitive Assessment ◽  
Mini Mental State Examination ◽  
Screening Tool ◽  
Montreal Cognitive Assessment ◽  
Cognitive Screening ◽  
State Examination

scholarly journals Comparing the Montreal Cognitive Assessment with Mini-Mental State Examination in Japanese Parkinson's disease patients

2014 ◽  
Vol 2 (2) ◽  
pp. 44-49 ◽  
Author(s):  
Kouichi Ohta ◽  
Takashi Osada ◽  
Yukito Shinohara ◽  
Norihiro Suzuki ◽  
Kazushi Takahashi ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mental State ◽  
Cognitive Assessment ◽  
Mini Mental State Examination ◽  
Montreal Cognitive Assessment ◽  
State Examination

scholarly journals Montreal Cognitive Assessment scale in patients with Parkinson Disease with normal scores in the Mini-Mental State Examination

2019 ◽  
Vol 13 (1) ◽  
pp. 78-81 ◽  
Author(s):  
Krisly Arguedas Vásquez ◽  
Erick Miranda Valverde ◽  
Daniel Valerio Aguilar ◽  
Henri-Jacques Hernández Gabarain
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Mental State ◽  
Cognitive Assessment ◽  
Mini Mental State Examination ◽  
Montreal Cognitive Assessment ◽  
Screening Tests ◽  
Study Results ◽  
State Examination

ABSTRACT. Several screening tests have been used for cognitive evaluation in Parkinson’s disease (PD). Objective: To evaluate the usefulness of the Montreal Cognitive Assessment (MoCA) in patients with Parkinson’s disease and no cognitive impairment complaints. Methods: A total of 40 PD patients with no complaints of cognitive problems were included. Patients were selected using the Mini-Mental State Examination (MMSE) and the MoCA was then administered. Results: 80% of patients exhibited Mild Cognitive Impairment (MCI) according to the MoCA. Statistically significant differences in visuospatial, attention and delayed recall functions were evident between the normal and abnormal MoCA groups. Conclusion: The study results suggest that MoCA may be a good screening test in patients with PD who do not present cognitive complaints.

scholarly journals Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson’s Disease

2019 ◽  
Vol 47 (4-6) ◽  
pp. 187-197 ◽  
Author(s):  
Achinoam Faust-Socher ◽  
Sarah Duff-Canning ◽  
Arthur Grabovsky ◽  
Melissa J. Armstrong ◽  
Brandon Rothberg ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Decline ◽  
Mental State ◽  
Gold Standard ◽  
Cognitive Assessment ◽  
Mini Mental State Examination ◽  
Neuropsychological Testing ◽  
Montreal Cognitive Assessment ◽  
State Examination

Background: Clinical monitoring of patients with Parkinson’s disease (PD) for cognitive decline is an important element of care. The Montreal Cognitive Assessment (MoCA) has been proposed to be a sensitive tool for assessing cognitive impairment in PD. The aim of our study was to compare the responsiveness of the MoCA to decline in cognition to the responsiveness of the Mini Mental State Examination (MMSE) and the Scales for Outcomes of Parkinson’s disease-cognition (SCOPA-Cog). Methods: PD patients without dementia were enrolled at 6 North American movement disorders centers between 2008 and 2011. Participants received annual evaluations including the MoCA, MMSE, and SCOPA-Cog followed by formal neuropsychological testing. The gold standard for change in cognition was defined as the change on the neuropsychological test scores over the annual assessments. The Reliable Change Method was used to provide an estimate of the probability that a given difference score would be obtained by chance. The sensitivity of the MoCA, MMSE, and SCOPA-Cog to change was quantified using receiver operating characteristics (ROC) curves. Results: One hundred seventeen patients were included in the analysis. Participants were followed at mean intervals of 11 ± 2 months for a median of 2 (maximum 5) visits. According to the reliable change index, 56 intervals of cognitive testing showed a decline in global cognition. ROC analysis of change in MoCA, MMSE, and SCOPA-Cog global scores compared to gold standard testing found an area under the curve (AUC) of 0.55 (95% CI 0.48–0.62), 0.56 (0.48–0.63), and 0.63 (0.55–0.70) respectively. There were no significant differences in the AUCs across the tests. The sensitivity of the MoCA, MMSE, and SCOPA-Cog to change at various thresholds for decline in scores reached a maximum of 71% for a cut-off of 1 point change on the SCOPA-Cog. Conclusion: Using neuropsychological testing as a gold standard comparator, the performance of the MoCA, MMSE, and SCOPA-Cog for detecting decline in non-demented PD patients over a 1-year interval is poor. This has implications for clinical practice; stable scores may not be taken as reassurance of the absence of cognitive decline.

Sign in / Sign up

Export Citation Format

Share Document